Kite Pharma, Inc. announced that it has entered into a strategic partnership with Vitruvian Networks, Inc. to create a software solution for supporting commercial availability of T-cell therapies.
A look at Kite Pharma’s year-to-date share price movement shows that the stock has outperformed the Zacks classified Medical-Biomedical/Genetics industry. The company’s shares have lost 22.4% so far this year, which compares favorably with the industry’s 26.3% fall.
Under the latest partnership, the companies will design and develop a platform for patients, physicians and treatment centers to support the commercial use of FDA-approved T-cell therapies. Also, the software will be designed to support commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies, including Kite's lead candidate axicabtagene ciloleucel (KTE-C19).
As per the terms of the agreement, the companies will contribute resources and relevant experience for the partnership. Financial terms of the agreement were, however, not disclosed.
The tie-up will leverage Kite's expertise in clinical development, manufacturing, supply chain management and commercialization in engineered T-cell therapies with Vitruvian's hybrid expertise in cloud-based software and data analytics solutions in cell and gene therapy manufacturing and delivery.
Note that axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is being developed for the treatment of aggressive forms of non-Hodgkin’s lymphoma (NHL).
Earlier this month, the company announced that it has initiated the rolling submission of the Biologic License Application (BLA) in the U.S. for axicabtagene ciloleucel for the treatment of patients with relapsed/refractory aggressive B-cell NHL, who are ineligible for autologous stem cell transplant (ASCT). The rolling submission is expected to be complete by the end of the first quarter of 2017.
Kite pharma currently has Zacks Rank #3 (Hold).
Key Picks in the Sector
Some better-ranked stocks in the health care sector include Heska Corp. , Sucampo Pharmaceuticals, Inc. and Cambrex Corp. . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $158 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Image: Bigstock
Kite Pharma Enters into Partnership with Vitruvian Networks
Kite Pharma, Inc. announced that it has entered into a strategic partnership with Vitruvian Networks, Inc. to create a software solution for supporting commercial availability of T-cell therapies.
A look at Kite Pharma’s year-to-date share price movement shows that the stock has outperformed the Zacks classified Medical-Biomedical/Genetics industry. The company’s shares have lost 22.4% so far this year, which compares favorably with the industry’s 26.3% fall.
Under the latest partnership, the companies will design and develop a platform for patients, physicians and treatment centers to support the commercial use of FDA-approved T-cell therapies. Also, the software will be designed to support commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies, including Kite's lead candidate axicabtagene ciloleucel (KTE-C19).
As per the terms of the agreement, the companies will contribute resources and relevant experience for the partnership. Financial terms of the agreement were, however, not disclosed.
The tie-up will leverage Kite's expertise in clinical development, manufacturing, supply chain management and commercialization in engineered T-cell therapies with Vitruvian's hybrid expertise in cloud-based software and data analytics solutions in cell and gene therapy manufacturing and delivery.
Note that axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is being developed for the treatment of aggressive forms of non-Hodgkin’s lymphoma (NHL).
Earlier this month, the company announced that it has initiated the rolling submission of the Biologic License Application (BLA) in the U.S. for axicabtagene ciloleucel for the treatment of patients with relapsed/refractory aggressive B-cell NHL, who are ineligible for autologous stem cell transplant (ASCT). The rolling submission is expected to be complete by the end of the first quarter of 2017.
KITE PHARMA INC Price and Consensus
KITE PHARMA INC Price and Consensus | KITE PHARMA INC Quote
Kite pharma currently has Zacks Rank #3 (Hold).
Key Picks in the Sector
Some better-ranked stocks in the health care sector include Heska Corp. , Sucampo Pharmaceuticals, Inc. and Cambrex Corp. . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%.
Sucampo’s earnings estimates increased from $1.03 to $1.22 for 2016 and from $1.30 to $158 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 35.55%.
Cambrex’s earnings estimates increased from $2.46 to $2.55 for 2016 and from $2.91 to $3.06 for 2017 over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>